Status:
NOT_YET_RECRUITING
Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.
Lead Sponsor:
Peking University People's Hospital
Conditions:
AML
Elderly
Eligibility:
All Genders
55+ years
Phase:
NA
Brief Summary
Elderly AML patients receiving conventional chemotherapy have poor prognosis. Allo-HSCT offers better long-term survival than chemotherapy, while high TRM limits its use. Current research focuses more...
Detailed Description
The prognosis of elderly patients with acute myeloid leukemia (AML) undergoing conventional chemotherapy is poor. Compared with chemotherapy, allogeneic hematopoietic stem cell transplantation (allo-H...
Eligibility Criteria
Inclusion
- \- (a)Diagnosed with AML in first complete remission (CR1). (b)Age ≥55 years. (c)Availability of an haploidentical donor, first transplant, no matched sibling or unrelated donor.
- (d)Willingness to provide written informed consent.
Exclusion
- (a) Uncontrolled active infection. (b) Secondary AML. (c)Refusal to provide informed consent.
Key Trial Info
Start Date :
May 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2027
Estimated Enrollment :
307 Patients enrolled
Trial Details
Trial ID
NCT06946602
Start Date
May 20 2025
End Date
October 31 2027
Last Update
May 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China